Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration

Neurobiology of Disease

Volumn 15, Issue 1, 2004, Pages 11-20

  Wilcock, Donna M ^a   Munireddy, Sanjay K ^a   Rosenthal, Arnon ^b   Ugen, Kenneth E ^a   Gordon, Marcia N ^a   Morgan, Dave ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Rinat Neuroscience Corporation   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Amyloid deposits; Anti A ; Microglia

Indexed keywords

AMYLOID BETA ANTIBODY; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MINOCYCLINE; NCX 2216; NITRO FERULO FLURBIPROFEN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; IMMUNOTHERAPY; MICROGLIA; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 1642497601     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2003.09.015     Document Type: Article

References (40)

1. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., Weiner M.F., Farlow M.R., Sano M., Grundman M., Thal L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology. 54(3):2000;588-593.
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S.T., Hampel H., Hull M., Landreth G., Lue L.F., Mrak M., Mackenzie I.R., McGeer P.L., O'Banion K., Patcher J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
3. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., Hyman B.T. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:2001;369-372.
4. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22:2002;2223-2226.
5. Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., Morley J.E. Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides. 23:2002;2223-2226.
6. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
7. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2023-2028.
8. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V.P., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:1999;271-276.
9. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzmann D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8850-8855.
10. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-457.
11. Frenkel D., Balass M., Katchalski-Katzir E., Solomon B. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 95:1999;136-142.
12. Golde T.E., Eckman C.B., Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta. 1502:2000;172-187.
13. Gordon M.N., Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.W., Connor K., Melachrino J., O'Callaghan J.P., Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp. Neurol. 173:2002;183-195.
14. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress on the road to therapeutics. Science. 297:2002;353-356.
15. Hauss-Wegrzyniak B., Willard L.B., Del Soldato P., Pepeu G., Wenk G.L. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res. 815:1999;36-43.
16. He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909:2001;187-193.
17. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., Davey G., Moritz E., Nitsch R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8:2002;1270-1275.
18. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:2003;547-554.
19. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:1998;97-100.
20. Holtzman D.M., Bales K.R., Paul S.M., DeMattos R.B. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv. Drug Delivery Rev. 7:2002;1603-1613.
21. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
22. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., Gordon M.N. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22:2002;2246-2254.
23. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
24. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:2003;486-489.
25. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:2002;6331-6335.
26. Lue L.F., Walker D.G. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J. Neurosci. Res. 70:2002;599-610.
27. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862.
28. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
29. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:2003;448-452.
30. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 61:2003;46-54.
31. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev., Neurosci. 3:2002;824-828.
32. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
33. Schimmer B.P., Parker K.L. Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Hardman J.G., Limbird L.E., Gilman A.G. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 2001;1649-1677 McGraw-Hill, New York.
34. Solomon B., Koppel R., Frenkel D., Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4109-4112.
35. Tanaka J., Fujita H., Matsuda S., Toku K., Sakanaka M., Maeda N. Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia. 20:1997;23-37.
36. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21:2001;2580-2588.
37. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
38. Wilcock D.M., Gordon M.N., Ugen K.E., Gottschall P.E., DiCarlo G., Dickey C., Boyett K.W., Jantzen P.T., Connor K.E., Melachrino J., Hardy J., Morgan D. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 20:2001;731-736.
39. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms independent of and associated with microglial activation. J. Neurosci. 213:2003;3745-3751.
40. Yrjanheikki J., Keinanen R., Pelikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 99:1998;10837-10842.